ApplicationSiheung-si, South KoreaFounded 2013· One of 414 Application companies tracked by AMPulse
A global leader in regenerative medicine that leverages proprietary 3D bioprinting technology to develop bioresorbable medical devices, tissue-derived bio-inks, and cell-based therapeutics.
CEO / Founder
Won-Soo Yun (윤원수)
Team Size
51-200
Stage
Established
Total Funding
$59.62M
Key Investors
Korea Investment Partners, eBest Investment & Securities, NAU IB Capital, DSC Investment, Hanbit Investment, C&Venture Partners, BTC Investment, KB Securities Co., Ltd, NH Investment & Securities Co., Ltd., Shinhan Bank, The Korea Securities Finance Corporation
Technology & Products
Key Products
Bioresorbable medical devices (e.g., cranial implants), tissue-derived bio-inks, and cell-based therapeutics.
Technological Advantage
Proprietary dECM bio-ink technology provides a biomimetic environment that outperforms synthetic alternatives in cell viability and tissue integration; maintains a vertically integrated model from bio-ink production to clinical application.
Differentiation
Value Proposition
Provides patient-specific, bioresorbable implants and organoids that minimize immune rejection and promote natural tissue regeneration, significantly improving surgical outcomes and drug development accuracy.
How They Differentiate
Extensive patent portfolio and government backing for artificial organ development
Market & Competition
Target Customers
Hospitals, medical device companies, research institutions
Industry Verticals
Bioprinting, Medical Devices, Tissue Engineering, Regenerative Medicine
Competitors
ROKIT Healthcare, CELLINK, Organovo
Growth & Milestones
Growth Metrics
$14.7M trailing 12-month revenue, $41.7M market cap (Oct 2025)
Major Milestones
Founded 2013, Series B funding, KOSDAQ listing, 8.4B won government research support, 100+ patents
Notable Customers
Ethicon (Johnson & Johnson), B. Braun Korea, CJ CheilJedang, HK inno.N
T&R Biofab occupies a distinctive position at the intersection of 3D bioprinting and regenerative medicine, focusing on patient-specific, bioresorbable implants that promote natural tissue regeneration rather than permanent hardware. Unlike many bioprinting firms that supply only bio-inks or research tools, T&R Biofab maintains a vertically integrated model spanning bio-ink production, implant design, and clinical application, with a stated goal of developing artificial organs using iPS cells.
The company's core technology is material extrusion (MEX) bioprinting, applied to produce tissue-derived decellularized extracellular matrix (dECM) bio-inks. These inks are designed to mimic the native cellular environment, improving cell viability and tissue integration compared to synthetic alternatives. Key products include bioresorbable cranial implants, tissue-derived bio-inks, and cell-based therapeutics. T&R Biofab reports over 150 global patents, with notable IP covering 3D-printed liver organoids and biodegradable surgical mesh designs.
T&R Biofab's target customers include hospitals, medical device companies, and research institutions. Named partners include Ethicon (Johnson & Johnson) for global distribution of 3D-printed surgical mesh, B. Braun Korea for bioresorbable devices, and CJ CheilJedang for cultured meat applications. The company also acquired Blisspack in 2024 to extend bioprinting into cosmetics and packaging. As of October 2025, T&R Biofab reported trailing twelve-month revenue of $14.7 million and a market cap of $41.7 million, with a KOSDAQ listing and over $59 million in total disclosed funding.
T&R Biofab's strategic moat rests on its extensive patent portfolio and government-backed research support, including 8.4 billion won in government funding. However, the company faces competitive pressure from established bioprinting firms such as CELLINK, Organovo, and ROKIT Healthcare, all of which are also pursuing clinical translation. The key open question is whether T&R Biofab can scale its dECM-based platform beyond cranial implants into larger organ applications and secure regulatory approvals in overseas markets.